BETA3LVH研究—β3-AR激动剂米拉贝隆治疗结构性心脏病坚拒亦无过

最后，针对现有的数据集分析结论，Balligand名誉教授提出未来就会的数据集分析应该包括晚期哮喘哮喘，或者常用不够很低浓度的米维茨良，又或者常用不够强效的β3-AR低剂量。因而，此项数据集分析仍有进一步充分利用的年前提和推进的价值。

参考文献：（上下滑动查看不够多）

[1]The abstract ‘A randomied, multicenter, placebo-controlled trial of the beta3 adrenergic agonist, mirabegron on left ventricular mass and diastolic function in patients with structural heart disease: the Beta3-LVH trial’ will be presented during the session ‘Emerging Heart Failure Science’ on Monday 7 November at 08:00 to 09:00 (Central Time Zone). Mirabegron is safe but fails to prevent remodelling in patients with mild heart failure

[2] Mirabegron is safe but fails to prevent remodelling in patients with mild heart failure[EB/OL]. Mirabegron is safe but fails to prevent remodelling in patients with mild heart failure (escardio.org)

[3]Pouleur AC, Anker S, Brito D, et al. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH). ESC Heart Fail. 2018;5:830–841.

[4]Bundgaard H, Axelsson Raja A, Iversen K, et al. Hemodynamic effects of cyclic guanosine monophosphate-dependent signaling through β3 adrenoceptor stimulation in patients with advanced heart failure: A randomized invasive clinical trial. Circ Heart Fail. 2022;15:e009120.